从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.70倍，行业中值39.08倍，拱东医疗排 名第58位。 股东方面，截至2025年3月31日，拱东医疗股东户数8909户，较上次增加735户，户均持股市值35.28万 元，户均持股数量2.76万股。 8月8日，拱东医疗今日收盘20.96元，上涨3.76%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到30.02倍，创33天以来新低，总市值46.22亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入2.64亿元，同比-2.74%；净利润2741.25万元，同 比-39.23%，销售毛利率32.40%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13拱东医疗30.0226.932.6746.22亿行业平均 55.7051.864.84117.31亿行业中值39.0838.492.8857.46亿1九安医疗11.1411.270.88188.05亿2英科医疗 15.5716.791.39246.03亿3山东药玻16.0616.111.85151.90亿4振德医疗16.3115.371.0459.21亿5新华医疗 16.44 ...

Core Viewpoint - Zhejiang Gongdong Medical Instrument Co., Ltd. has completed the registration change and obtained a new business license, reflecting an increase in registered capital from 157,578,415 yuan to 220,492,949 yuan, indicating a significant growth in the company's financial structure [1][2]. Group 1: Company Changes - The company held its 14th meeting of the third board of directors on April 21, 2025, and the annual shareholders' meeting on May 27, 2025, where the proposal to change the registered capital and amend the articles of association was approved [1]. - The total number of shares has increased from 157,578,415 shares to 220,492,949 shares following the capital change [1]. Group 2: Business License Information - The new business license issued by the Zhejiang Provincial Market Supervision Administration includes the updated registered capital of 220,492,949 yuan and confirms the company type as a listed other joint-stock company [1]. - The company was established on August 17, 2009, and is located at No. 10, Beiyuan Avenue, Huangyan District, Taizhou City, Zhejiang Province [1]. Group 3: Business Scope - The company is authorized to produce and operate Class II and Class III medical devices, as well as disposable medical supplies and food-grade plastic packaging containers [1]. - The general business activities include sales of Class I and Class II medical devices, production of protective equipment for medical personnel, and various technical services and consulting [1].

Summary of Key Points Core Viewpoint The articles outline the corporate governance structure, operational objectives, and shareholder rights of Zhejiang Gongdong Medical Technology Co., Ltd., emphasizing the company's commitment to high-quality medical products and services while adhering to legal regulations. Group 1: Company Overview - The company is established as a joint-stock limited company based on the original Zhejiang Gongdong Medical Technology Co., Ltd. and registered with the Zhejiang Provincial Market Supervision Administration [3] - The company was approved by the China Securities Regulatory Commission to issue 20 million shares of ordinary stock to the public on August 21, 2020, and was listed on the Shanghai Stock Exchange on September 16, 2020 [3][4] - The registered capital of the company is RMB 220,492,949 [4] Group 2: Business Objectives and Scope - The company's business objective is to adhere to the principle of "high quality, high efficiency, mutual development, and common prosperity," striving for excellence in providing outstanding products and services to the medical industry [5] - The company's operational scope includes the production and sale of various medical devices, including Class II and Class III medical devices, as well as disposable medical supplies and food-grade plastic packaging [5] Group 3: Shareholder Rights and Governance - The company's articles of association serve as a legally binding document that regulates the rights and obligations of the company, shareholders, directors, supervisors, and senior management [5] - Shareholders have the right to receive dividends, participate in shareholder meetings, supervise the company's operations, and request information [15] - The company must hold annual and extraordinary shareholder meetings, with specific procedures for proposing and voting on resolutions [19][29] Group 4: Board of Directors and Management - The board of directors is responsible for the company's strategic decisions, including the election and remuneration of directors and supervisors [18] - The company has established a management structure that includes a general manager and other senior management personnel, who are accountable to the board of directors [5][18] Group 5: Financial and Audit Regulations - The company is required to maintain a financial accounting system, conduct internal audits, and appoint external auditors [5] - The articles specify the procedures for capital increases, reductions, and share repurchases, ensuring compliance with relevant laws and regulations [10][11]

Company Overview - Company name: Zhejiang Gongdong Medical Instrument Co., Ltd. specializes in the research, production, and sales of disposable medical consumables [1] - Main products include medical testing, blood collection, sampling, medical care, drug packaging, and others [1] Financial Performance - As of Q1 2025, the company reported revenue of 264 million yuan, a year-on-year decrease of 2.74% [1] - Net profit for the same period was 27.41 million yuan, down 39.23% year-on-year [1] - The sales gross margin stood at 32.40% [1] Market Position - The company's current stock price is 19.83 yuan, with a PE ratio of 28.40 times [1] - Total market capitalization is 4.372 billion yuan [1] - Compared to the industry average PE of 54.56 times and median PE of 37.54 times, the company ranks 56th in the medical device sector [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 8,909, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

浙江拱东医疗器械股份有限公司 章 程 二零二五年四月 目 录 第一章 总 则 第二章 经营宗旨和范围 第三章 股 份 第四章 股东和股东大会 第五章 董事会 第六章 总经理及其他高级管理人员 第七章 监事会 第八章 财务会计制度、利润分配和审计 第九章 通知和公告 第十章 合并、分立、增资、减资、解散和清算 第十二章 附 则 1 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第一节 股东 第二节 股东大会的一般规定 第三节 股东大会的召集 第四节 股东大会的提案与通知 第五节 股东大会的召开 第六节 股东大会的表决和决议 第一节 董 事 第二节 董事会 第一节 监 事 第二节 监事会 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第一节 通 知 第二节 公 告 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司（以下 简称"公司"）。 公司系在原浙江拱东医疗科技有限公司的基础上变更设立的股份有限公司, 在 浙 江 省 市 场 监 督 管 理 局 注 册 登 记 ， 现 持 有 统 一 社 会 信 用 代 码 为 91331003148185689U 的《营业执照》 ...

证券代码：605369 证券简称：拱东医疗 公告编号：2025-024 住所：浙江省台州市黄岩区北院大道 10 号 浙江拱东医疗器械股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日 召开公司第三届董事会第十四次会议，2025 年 5 月 27 日召开公司 2024 年年度 股东大会，审议通过了《关于变更注册资本并修订〈公司章程〉的议案》等议案， 公司注册资本由原来的 157,578,415 元变更为 220,492,949 元，公司股份总数由原 来的 157,578,415 股变更为 220,492,949 股。具体内容敬请查阅公司 2025 年 4 月 22 日、2025 年 5 月 28 日披露于上海证券交易所网站（www.sse.com.cn）《关于 变更公司注册资本并修订〈公司章程〉的公告》（公告编号：2025-016）、《2024 年年度股东大会决议公告》（公告编号：2025-021）。 公司已于近日完成工商变更、备案登记手续，并取得了浙江省市场监督管理 局换发的《营业执照》，新取得的《营业执照》相关登记信息如下： 名称：浙江拱东医疗器械股份有限公司 注册资本：贰亿贰仟零肆拾玖万贰 ...

Core Insights - The medical device sector experienced a 0.8% increase on July 7, with a net capital outflow of 229.15 million [1] - A total of 75 stocks in the sector rose, while 44 stocks declined [1] Sector Performance - The top ten decliners in the sector included: - Rejing Bio (-6.14%) - Gongdong Medical (-4.2%) - Botao Bio (-3.67%) - Mindray Medical (-3.3%) - Ruimai Te (-3.28%) - BGI Genomics (-3.2%) - Xinmai Medical (-2.73%) - Yuyue Medical (-2.66%) - Xiangyu Medical (-2.59%) - Berry Genomics (-2.53%) [1][1] Stock Highlights - Notable stocks with significant movements included: - Baolite: Current price 9.95, up 0.028, with net capital of 842.20 million, accounting for 27.77% - Wuzhou Medical: Current price 38.61, up 19.99, with net capital of 3131.39 million, accounting for 17.35% - Jigaofazhan: Current price 3.36, up 10.16, with net capital of 5097.91 million, accounting for 38.75% [1][1][1]

Company Overview - Company name: Zhejiang Gongdong Medical Instrument Co., Ltd. specializes in the research, production, and sales of disposable medical consumables [1] - Main products include medical testing, blood collection, sampling, medical care, drug packaging, and others [1] Financial Performance - As of Q1 2025, the company reported revenue of 264 million yuan, a year-on-year decrease of 2.74% [1] - Net profit for the same period was 27.41 million yuan, down 39.23% year-on-year [1] - The sales gross margin stood at 32.40% [1] Market Position - The company's closing stock price on July 4 was 20.72 yuan, with a PE ratio of 29.68 times [1] - The total market capitalization is 4.569 billion yuan [1] - In comparison, the average PE ratio for the medical device industry is 51.05 times, with a median of 36.62 times, placing Gongdong Medical at the 66th position in the industry [1][2] Institutional Holdings - As of Q1 2025, four institutions hold shares in Gongdong Medical, including two funds, with a total holding of 14.5259 million shares valued at 402 million yuan [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Gongdong Medical, which has a closing price of 19.68 yuan and a rolling PE ratio of 28.19 times, with a total market value of 4.339 billion yuan [1][2] - Gongdong Medical ranks 61st in the medical device industry, which has an average PE ratio of 51.29 times and a median of 37.02 times [1][2] - As of March 31, 2025, Gongdong Medical has 8,909 shareholders, an increase of 735 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Gongdong Medical specializes in the research, production, and sales of disposable medical consumables, with main products including medical testing, blood collection, collection, medical care, and drug packaging [1] - In the latest quarterly report for Q1 2025, Gongdong Medical reported an operating income of 264 million yuan, a year-on-year decrease of 2.74%, and a net profit of 27.41 million yuan, down 39.23% year-on-year, with a gross profit margin of 32.40% [1]

Core Viewpoint - The legal opinion letter issued by Zhejiang Tiance Law Firm confirms that Zhejiang Gongdong Medical Devices Co., Ltd.'s differentiated equity distribution plan for the 2024 profit distribution complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [1][4][7]. Group 1: Differentiated Equity Distribution - The company plans to repurchase shares using self-owned funds through centralized bidding, with the repurchased shares intended for employee stock ownership plans or equity incentives [4]. - As of the date of the legal opinion, the number of shares in the repurchase account is 292,080, accounting for 0.19% of the total share capital of 157,578,415 shares [4]. - The repurchased shares will not participate in the 2024 profit distribution, leading to a need for special handling of the differentiated equity distribution [4][5]. Group 2: Profit Distribution and Repurchase Amount - The company distributed a total cash dividend of 109,813,154.50 yuan for the first half of 2024, with the total cash dividend and repurchase amount combined reaching 145,810,244.10 yuan, which is 84.95% of the net profit attributable to shareholders [5]. - The repurchase amount for the year is 35,997,089.60 yuan, which is considered in the cash dividend calculation [5]. Group 3: Calculation Basis for Differentiated Equity Distribution - The total share capital as of the date of the legal opinion is 157,578,415 shares, with 157,286,335 shares participating in the distribution [6]. - The reference price for ex-rights and ex-dividends is calculated based on the previous closing price and cash dividends, resulting in an actual distribution reference price of 19.1714 yuan per share [6][7]. - The impact of the differentiated equity distribution on the reference price is minimal, with an absolute value of less than 1% [7]. Group 4: Conclusion - The legal opinion concludes that the differentiated equity distribution plan adheres to the Company Law, Securities Law, and relevant regulatory guidelines, ensuring the protection of the interests of the company and its shareholders [7].